Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 11, 2014, Pages 1766-1775

  Li, Zheng ^a   Jiang, Jian Dong ^b   Kong, Wei Jia ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

AMP activated protein kinase (AMPK); Berberine; Low density lipoprotein (LDL) receptor; Raf 1; Ras

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; BERBERINE; COMPOUND C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MANUMYCIN; MANUMYCIN A; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; POLYENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIVER CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; CELL LINE; HUMANS; HYPERLIPIDEMIAS; LIVER; MALE; POLYENES; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; UP-REGULATION;

EID: 84910068641     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00412     Document Type: Article

References (41)

1. Defesche JC. Low-density lipoprotein receptor - its structure, function, and mutations. Semin. Vasc. Med., 4, 5-11 (2004), Review.
2. Tolleshaug H, Goldstein JL, Schneider WJ, Brown MS. Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia. Cell, 30, 715-724 (1982).
3. Kong WJ, Liu J, Jiang JD. Human low-density lipoprotein receptor gene and its regulation. J. Mol. Med. (Berl.), 84, 29-36 (2006), Review.
4. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med., 10, 1344-1351 (2004).
5. Yao J, Kong W, Jiang J. Learning from berberine: Treating chronic diseases through multiple targets. Sci. China Life Sci., doi: 10.1007/s11427-013-4568-z (2013), Review.
6. Yin J, Ye J, Jia W. Effects and mechanisms of berberine in diabetes treatment. Acta Pharmaceutica Sinica B, 2, 327-334 (2012), Review.
7. Liu Y, Zhang L, Song H, Ji G. Update on berberine in nonalcoholic fatty liver disease. Evid. Based Complement. Alternat. Med., 2013, 308134 (2013), Review.
8. Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid. Based Complement. Alternat. Med., 2014, 289264 (2014), Review.
9. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am. J. Physiol. Endocrinol. Metab., 294, E148-E156 (2008).
10. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH, Li J, Ye JM. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 57, 1414-1418 (2008).
11. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res., 47, 1281-1288 (2006).
12. Krepinsky JC, Li Y, Tang D, Liu L, Scholey J, Ingram AJ. Stretch-induced Raf-1 activation in mesangial cells requires actin cytoskeletal integrity. Cell. Signal., 17, 311-320 (2005).
13. Aziz R, Rafiq MT, Yang J, Liu D, Lu L, He Z, Daud MK, Li T, Yang X. Impact assessment of cadmium toxicity and its bioavailability in human cell lines (Caco-2 and HL-7702). Biomed. Res. Int., 2014, 839538 (2014).
14. Kong W, Abidi P, Kraemer FB, Jiang JD, Liu J. In vivo activities of cytokine oncostatin M in the regulation of plasma lipid levels. J. Lipid Res., 46, 1163-1171 (2005).
15. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, Zhao LX, Pan HN, Jiang JD. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism, 57, 1029-1037 (2008).
16. Zang M, Hayne C, Luo Z. Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J. Biol. Chem., 277, 4395-4405 (2002).
17. Kumar A, Chambers TC, Cloud-Heflin BA, Mehta KD. Phorbol ester-induced low density lipoprotein receptor gene expression in HepG2 cells involves protein kinase C-mediated p42/44 MAP kinase activation. J. Lipid Res., 38, 2240-2248 (1997).
18. Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, Veal JM, Wood ER. The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett., 10, 223-226 (2000).
19. Zarich N, Oliva JL, Martínez N, Jorge R, Ballester A, Gutiérrez-Eisman S, García-Vargas S, Rojas JM. Grb2 is a negative modulator of the intrinsic Ras-GEF activity of hSos1. Mol. Biol. Cell, 17, 3591-3597 (2006).
20. Zhou JM, Pan QC, Yang XP, Liu ZC, Liao DF, Fu LW, Liang YJ. Correlation between inhibitory effect of manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway. Ai Zheng, 21, 364-368 (2002).
21. Chen BC, Yu CC, Lei HC, Chang MS, Hsu MJ, Huang CL, Chen MC, Sheu JR, Chen TF, Chen TL, Inoue H, Lin CH. Bradykinin B2 receptor mediates NF-kappaB activation and cyclooxygenase-2 expression via the Ras/Raf-1/ERK pathway in human airway epithelial cells. J. Immunol., 173, 5219-5228 (2004).
22. Wang HM, Mehta S, Bansode R, Huang W, Mehta KD. AICAR positively regulate glycogen synthase activity and LDL receptor expression through Raf-1/MEK/p42/44MAPK/p90RSK/GSK-3 signaling cascade. Biochem. Pharmacol., 75, 457-467 (2008).
23. Su H, McClarty G, Dong F, Hatch GM, Pan ZK, Zhong G. Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids. J. Biol. Chem., 279, 9409-9416 (2004).
24. Sathishkumar K, Yallampalli U, Elkins R, Yallampalli C. Raf-1 kinase regulates smooth muscle contraction in the rat mesenteric arteries. J. Vasc. Res., 47, 384-398 (2010).
25. Büscher D, Hipskind RA, Krautwald S, Reimann T, Baccarini M. Ras-dependent and -independent pathways target the mitogenactivated protein kinase network in macrophages. Mol. Cell. Biol., 15, 466-475 (1995).
26. Chen D, Waters SB, Holt KH, Pessin JE. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J. Biol. Chem., 271, 6328-6332 (1996).
27. Vanderkuur JA, Butch ER, Waters SB, Pessin JE, Guan KL, Carter-Su C. Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation. Endocrinology, 138, 4301-4307 (1997).
28. Frassanito MA, Mastromauro L, Cusmai A, Dammacco F. Blockade of the Ras pathway by manumycin, a farnesyltransferase inhibitor, overcomes the resistance of myeloma plasma cells to Fas-induced apoptosis. Clin. Exp. Med., 4, 174-182 (2005).
29. Yan K, Zhang C, Feng J, Hou L, Yan L, Zhou Z, Liu Z, Liu C, Fan Y, Zheng B, Xu Z. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur. J. Pharmacol., 661, 1-7 (2011).
30. Chang KS. Down-regulation of c-Ki-ras2 gene expression associated with morphologic differentiation in human embryonal carcinoma cells treated with berberine. J. Formos. Med. Assoc., 90, 10-14 (1991).
31. Buitrago CG, Pardo VG, de Boland AR, Boland R. Activation of RAF-1 through Ras and protein kinase Calpha mediates 1alpha,25(OH)2-vitamin D3 regulation of the mitogen-activated protein kinase pathway in muscle cells. J. Biol. Chem., 278 , 2199-2205 (2003).
32. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, Hiroi Y, Mizuno T, Yazaki Y. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J. Biol. Chem., 271, 33592-33597 (1996).
33. Cheng JJ, Wung BS, Chao YJ, Wang DL. Sequential activation of protein kinase C (PKC)-alpha and PKC-epsilon contributes to sustained Raf/ERK1/2 activation in endothelial cells under mechanical strain. J. Biol. Chem., 276, 31368-31375 (2001).
34. Nourshargh S, Hoult JR. Divergent effects of co-carcinogenic phorbol esters and a synthetic diacylglycerol on human neutrophil chemokinesis and granular enzyme secretion. Br. J. Pharmacol., 91, 557-568 (1987).
35. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, Wang YM, Shan N, Zhou ZX, Yang P, You XF, Li ZR, Si SY, Zhao LX, Pan HN, Jiang JD. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism, 58, 109-119 (2009).
36. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS, Kim JB. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab., 296, E955-E964 (2009).
37. Cheng CC, Hsueh CM, Liang KW, Ting CT, Wen CL, Hsu SL. Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells. Eur. J. Pharmacol., 650, 519-525 (2011).
38. Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem. Biophys. Res. Commun., 362 , 853-857 (2007).
39. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, Nan FJ, Li J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim. Biophys. Acta, 1760, 1682-1689 (2006).
40. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler. Thromb. Vasc. Biol., 25, 2170-2176 (2005).
41. Zhao W, Xue R, Zhou ZX, Kong WJ, Jiang JD. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed. Pharmacother., 62, 730-731 (2008).